Theriva Biologics, Inc. (TOVX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 7, 2025, details the consummation of a public equity offering by Theriva Biologics, Inc. The offering closed on May 8, 2025. The Company is incorporated in Nevada and its common stock trades on the NYSE American under the symbol "TOVX."
Key Financial Metrics and Capital Structure
- Gross Proceeds: Approximately $7.5 million raised from the offering.
- Securities Issued:
- 1,990,900 shares of Common Stock.
- Pre-Funded Warrants to purchase up to 4,827,280 shares of Common Stock.
- Common Stock purchase warrants to purchase up to 6,818,180 shares of Common Stock.
- Offering Prices:
- Common Stock and associated Common Warrant: $1.10 per unit.
- Pre-Funded Warrant and associated Common Warrant: $1.099 per unit.
- Transaction Costs: Placement agent fee of 7.0% of gross proceeds; reimbursement of up to $100,000 for legal and out-of-pocket expenses.
- Outstanding Shares: 4,773,358 shares of Common Stock outstanding immediately following the closing (excluding warrant exercises).
Material Changes and Use of Proceeds
The primary material change is the significant increase in equity capital and potential dilution from the issuance of shares and warrants. The Company intends to use the net proceeds primarily for working capital and general corporate purposes. Specific allocations include research and development, manufacturing scale-up, and potential investments in or acquisitions of other products, businesses, or technologies.
Management Commentary, Risks, and Contingencies
- Lock-Up Provisions: The Company and its executive officers/directors are subject to a 90-day lock-up period restricting the sale of securities. Additionally, the Company is restricted from issuing new equity or engaging in "at-the-market" offerings for 6 months post-closing, with specific exceptions after 45 and 75 days.
- Warrant Terms: Common Warrants have an exercise price of $1.10 and expire 5 years from issuance. Pre-Funded Warrants are immediately exercisable at $0.001. Both include cashless exercise provisions and anti-dilution adjustments.
- Ownership Limits: Holders are restricted from exercising warrants if it would result in beneficial ownership exceeding 4.99% (or 9.99% with notice) of outstanding shares.
- Fundamental Transactions: Warrant holders have specific rights regarding repurchase at Black Scholes Value or conversion to consideration in the event of a fundamental transaction.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 7.0% placement fee and the $100,000 expense cap.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Confirm the dilution impact on existing shareholders given the issuance of ~6.8 million Common Warrants and ~4.8 million Pre-Funded Warrants.
- Monitor the Company's cash burn rate to assess the runway provided by the $7.5 million gross proceeds.
- Check for any subsequent filings regarding the exercise of Pre-Funded Warrants, which would immediately increase the share count.